Siemens Healthineers: UBS remains positive, lowers target

(CercleFinance.com) - UBS confirms its 'buy' recommendation on Siemens Healthineers, while lowering its target price from E60 to E56, a new target which nonetheless gives 14% upside potential for the German medical technology group's stock.


"We are disappointed by the Imaging miss which was driven as much by optimistic guidance assumptions as by delivery, but shares already reflect this", the broker says, seeing the stock's valuation "accommodating enough to reiterate buy".


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.